Strong Progress and Financial Update from Celldex Therapeutics
August 8, 2025 - 01:36
Celldex Therapeutics has announced significant advancements in its pipeline, showcasing impressive results from its Phase 2 CSU study. The data revealed a profound and sustained complete response in patients, along with an improved quality of life measured seven months after the conclusion of barzolvolimab dosing. This breakthrough underscores the company's commitment to developing innovative therapies.
In addition to the CSU study results, Celldex is anticipating further data from ongoing Phase 2 studies of barzolvolimab targeting eosinophilic esophagitis (EoE) and chronic inducible urticaria (CIndU). Furthermore, results from a Phase 1 study of CDX-622 in healthy volunteers are expected in the latter half of 2025. These upcoming data releases are highly anticipated by stakeholders and could have significant implications for the company’s future direction and product offerings.
The financial results reported for the second quarter of 2025 reflect the company's strong execution and strategic focus on advancing its clinical programs, positioning it well for continued growth in the biopharmaceutical landscape.
MORE NEWS
August 21, 2026 - 00:02
Broadcom Seeks More Than $60 Billion in Latest AI Debt DealBroadcom Inc. is negotiating with a consortium of lenders to secure upwards of $60 billion in new financing, a move aimed at bankrolling a major expansion of its artificial intelligence chip...
August 20, 2026 - 04:03
JPMorganChase to Present at the Barclays Global Financial Services ConferenceNEW YORK, August 19, 2026 - Doug Petno, who serves as Co-President of JPMorganChase and leads the firm`s Commercial & Investment Bank, is scheduled to appear at the Barclays Global Financial...
August 19, 2026 - 00:42
Sabalenka’s Coach Recalls Financial Sacrifices on Road to $50M CareerAryna Sabalenka has now banked more than fifty million dollars in career prize money, but the journey to that figure was far from glamorous. Her coach, Anton Dubrov, recently looked back on the...
August 18, 2026 - 04:03
Bending Spoons' Playbook: Buy Low—and HoldMost tech acquirers these days are looking for a quick flip. They buy a struggling app, cut costs, squeeze out whatever revenue they can, and then sell the shell to the next buyer within a year or...